Review
Immunology
Howard M. Johnson, Chulbul M. Ahmed
Summary: The field of antiviral therapeutics has focused on COVID-19, and the development of a vaccine has played a major role in reducing mortality and morbidity. The Pfizer drug paxlovid is the recommended treatment for early COVID-19. Additionally, the development of IFN mimetics and SOCS1/3 antagonists shows promise for broad spectrum antiviral activity.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Virology
Ana C. Alcala, Jose L. Maravillas, David Meza, Octavio T. Ramirez, Juan E. Ludert, Laura A. Palomares
Summary: Dengue is a common viral disease transmitted by mosquitoes. This study reveals that the dengue virus NS1 enters cells through the human HDL receptor, which has significant implications for viral replication and pathogenesis.
JOURNAL OF VIROLOGY
(2022)
Article
Gastroenterology & Hepatology
Sunil Taneja, Ajay Duseja, Manu Mehta, Arka De, Nipun Verma, Madhumita Premkumar, Radha K. Dhiman, Virendra Singh, Mini P. Singh, Radha K. Ratho, Raja Ramachandran, Vivek Kumar, Harbir S. Kohli
Summary: The study evaluated the safety and efficacy of Sofosbuvir plus Velpatasvir fixed-dose combination in treating CHC patients with ESRD on MHD. Results showed 100% of patients achieved ETR and 96% achieved SVR 12. All patients tolerated the combination without any serious adverse events.
LIVER INTERNATIONAL
(2021)
Review
Biochemistry & Molecular Biology
Mojisola Ogunnaike, Srijanee Das, Samiksha S. Raut, Ashrafi Sultana, Mohammad Ullah Nayan, Murali Ganesan, Benson J. Edagwa, Natalia A. Osna, Larisa Y. Poluektova
Summary: Chronic hepatitis B virus (HBV) infection can lead to the development of cirrhosis and hepatocellular carcinoma. Lifelong treatment with nucleotides/nucleoside antiviral agents is effective but adherence can be challenging. This review discusses recent advances in the development of long-acting formulations and curative strategies for HBV treatment, highlighting promising antivirals and genome editing approaches.
Review
Health Care Sciences & Services
Joo Hyun Oh, Dong Ah Park, Min Jung Ko, Jeong-Ju Yoo, Sun Young Yim, Ji-Hyun Ahn, Dae Won Jun, Sang Bong Ahn
Summary: The risk of HBV reactivation is higher in patients with HBV/HCV co-infection receiving DAA therapy, but can be reduced with prophylactic anti-HBV treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Immunology
Robert J. Wong, Harvey W. Kaufman, Justin K. Niles, Hema Kapoor, Robert G. Gish
Summary: Current treatment eligibility algorithms for chronic hepatitis B are complex and may contribute to missed opportunities for early antiviral therapy. Using a large US laboratory database, we propose a stepwise simplification of chronic hepatitis B treatment eligibility to be considered, aiming to improve timely treatment.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Medicine, General & Internal
Yanhua Tang, Hongyan Liang, Ge Zeng, Sheng Shen, Jian Sun
Summary: Chronic hepatitis B virus infection is a global health burden, and existing antiviral drugs can improve prognosis but have low success rates for functional cure and complete cure. Therefore, new antiviral drugs, including direct-acting antiviral drugs and immunotherapeutic approaches, are needed.
CHINESE MEDICAL JOURNAL
(2022)
Article
Chemistry, Multidisciplinary
Daniel Schiavone, Diana M. Kapkayeva, Qilan Li, Molly E. Woodson, Andreu Gazquez Casals, Lynda A. Morrison, John E. Tavis, Ryan P. Murelli
Summary: Polyoxygenated tropolones are promising lead structures or fragments for drug development due to their broad range of biological activity. The use of 3-hydroxy-4-pyrone-based oxidopyrylium cycloaddition chemistry provides a highly general strategy for tropolone synthesis, allowing the synthesis of functionalized tropolones through complementary benzyl alcohol-incorporating procedures.
CHEMISTRY-A EUROPEAN JOURNAL
(2022)
Article
Microbiology
Jyoti Gupta, Minnah Irfan, Niranjan Ramgir, K. P. Muthe, A. K. Debnath, Shabnam Ansari, Jaya Gandhi, C. T. Ranjith-Kumar, Milan Surjit
Summary: Zinc salts exhibit antiviral activity against HEV and HCV, with zinc oxide nanoparticles showing higher efficacy. These nanoparticles are noncytotoxic to cells and have potential therapeutic benefits for HEV and HCV.
FRONTIERS IN MICROBIOLOGY
(2022)
Review
Medicine, General & Internal
Pil Soo Sung, Eui-Cheol Shin
Summary: The use of DAAs in treating chronic HCV infection can lead to rapid changes in the phenotypes of NK and MAIT cells, potentially reducing their cytotoxicity against cancer cells. Additionally, DAAs treatment does not normalize the increased frequencies of regulatory T cells, which may contribute to local immunosuppression and hinder cancer cell clearance.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Chemistry, Multidisciplinary
Farzaneh Mohajerani, Botond Tyukodi, Christopher J. Schlicksup, Jodi A. Hadden-Perilla, Adam Zlotnick, Michael F. Hagan
Summary: In this study, computer simulations and analysis were used to reveal the assembly process of hepatitis B virus (HBV) and the mechanism of capsid polymorphism. The findings are important for understanding the HBV lifecycle and developing new antiviral drugs.
Review
Virology
Hui-Chun Li, Chee-Hing Yang, Shih-Yen Lo
Summary: The life cycle of the hepatitis C virus can be divided into several stages, including viral entry, protein translation, RNA replication, viral assembly, and release. The replication of HCV genomic RNA is regulated by various factors and has led to the development of direct-acting antivirals targeting the replication complex.
Article
Pharmacology & Pharmacy
Dimas F. Praditya, Mara Kloehn, Yannick Brueggemann, Lauren E. Brown, John A. Porco, Wenhan Zhang, Volker Kinast, Andreas Kirschning, Florian W. R. Vondran, Daniel Todt, Eike Steinmann
Summary: This study evaluated the antiviral properties of 205 synthetic rocaglate derivatives against HEV. At least 11 compounds showed inhibitory activities against HEV, with three amidino-rocaglates exhibiting strong antiviral activity against different genotypes of HEV. These compounds also showed better tolerance in normal liver cells and displayed additive effects when combined with ribavirin and interferon-α.
ANTIVIRAL RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Peng Huang, Yan Wang, Ming Yue, Zhijun Ge, Xueshan Xia, Andre J. Jeyarajan, Jacinta A. Holmes, Rongbin Yu, Chuanwu Zhu, Sheng Yang, Wenyu Lin, Raymond T. Chung
Summary: The HCV recurrence risk after achieving SVR with all-oral DAAs therapy is low, and the risk of HCV recurrence in high-risk and HIV/HCV-coinfected populations was driven by an increase in reinfection rather than late relapse.
LIVER INTERNATIONAL
(2021)
Article
Pharmacology & Pharmacy
David Durantel
Summary: This literature review focuses on recent findings and novel concepts on prospective therapies against hepatitis B virus (HBV) infections. The Taiwanese experience has demonstrated the effectiveness of constrained national HBV prophylactic vaccination programs in preventing HBV-induced end-stage liver disease. However, the number of individuals chronically infected with HBV remains high globally.
ANTIVIRAL RESEARCH
(2023)
